Drugs / SC-DARIC33
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05105152 | Nov 2021 → Feb 2028 expected | acute myeloid leukemia | Seattle Children's Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SC-DARIC33 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05105152 ↗ |
| Modality | Cell therapy | “autologous T cell product that has been genetically modified to express a Dimerizing Agent Regulated Immunoreceptor Complex (DARIC)” NCT05105152 ↗ |
| Route | Other | “Infusion with SC-DARIC33” NCT05105152 ↗ |